Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.

• Entecavir and imipenem alleviated LPS-induced cytokine storm syndrome. • Entecavir and imipenem mitigated LPS-induced acute lung injury. • Entecavir and imipenem inhibited LPS-stimulated TNF-α and IL-10 in hPBMC. • Entecavir and imipenem attenuated LPS-activated NF-κB. Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS. [ABSTRACT FROM AUTHOR]